Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGenetic & Molecular TestingCommunity Health Plan Washington Genetic Testing C…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ModifiedCommunity Health Plan WashingtonPolicy N/A

    Concert Genetic Testing Oncology: Molecular Analysis of Solid Tumors and Hematologic Malignancies

    Customize your policy alerts

    Sign up for all Community Health Plan Washington policy alerts

    Know when Community Health Plan Washington releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines coverage, coding examples, and clinical context for somatic molecular profiling of solid tumors and hematologic malignancies to identify driver mutations, tumor characteristics (TMB, MSI, fusions), and inform targeted therapy and monitoring.

    Policy Summary
    PayerCommunity Health Plan Washington
    PolicyMolecular Analysis of Solid Tumors and Hematologic Malignancies (coverage criteria)
    Policy CodePolicy N/A
    Change TypeMaterial updates to MRD, TMB, coding, and tumor-specific criteria
    Effective DateN/A
    Last ReviewNov 20, 2024
    Next Review DateNov 1, 2025
    Key ActionObtain prior authorization and document diagnosis, prior testing, and that results will change management when ordering listed panels or MRD/TMB testing.
    SourceLink
    POLICY UPDATE CHANGES

    Solid Tumor Minimal Residual Disease (MRD) Testing criteria and related guidance were added.

    Tumor Mutational Burden (TMB) section expanded with multiple NCCN guideline references and FDA label threshold.

    Multiple CPT/HCPCS and proprietary test code mappings were changed in the policy tables (e.g., additions 81457–81459 and CPT 0422U).

    Multiple tumor-specific coverage criteria were expanded or clarified to align with updated NCCN guidance.

    listedTumor-type agnostic panels
    81449RNA fusion panel (targeted)
    1/diagnosisMRD default frequency
    ≥10 mut/MbTMB-H threshold
    ~40+Codes referenced
    yesIncidental germline risk noted

    Coverage Criteria and Medical Necessity

    Tumor-Type Agnostic Solid Tumor Molecular Profiling Panels (medical necessity and repeat testing)

    Covered when the following grouped logic is met:

    I.A

    • A.1: Diagnosis is one of: recurrent, relapsed, refractory, metastatic, or advanced stage III/IV cancer; histiocytosis; non-small cell lung cancer (any stage); resectable or borderline resectable pancreatic adenocarcinoma; central nervous system tumor
    • A.2: Member is seeking further cancer treatment (e.g., therapeutic chemotherapy)
    I.B: Alternate covered scenarios: either (1) uterine neoplasm undergoing initial evaluation OR (2) gastrointestinal stromal tumor (GIST) that is negative for KIT and PDGFRA somatic mutations
    II: Repeat testing via a tumor-type agnostic solid tumor molecular profiling panel is medically necessary when the member has progression of: (1) advanced/metastatic NSCLC; OR (2) advanced/metastatic gastric adenocarcinoma; OR (3) metastatic prostate cancer
    III: Tumor-type agnostic solid tumor molecular profiling panels listed are investigational for all other indications

    Targeted RNA Fusion Panels (81449)

    RNA-specific fusion panels (5-50 genes) are covered when one of the listed diagnostic/workup conditions is met:

    I.A: Member has diagnosis or is undergoing workup for: adult or pediatric acute lymphoblastic leukemia (ALL); glioma; histiocytosis; sarcoma
    I.B: GIST AND tumor negative for KIT and PDGFRA somatic mutations
    I.C: NSCLC AND DNA-based NGS tumor profiling was negative for actionable mutations
    I.D: Metastatic or advanced solid tumor AND (1) there is a fusion-targeted therapy with regulatory approval for that cancer type OR (2) DNA-based panel testing was negative for oncogenic driver mutations
    II:

    Tumor-type agnostic panels: initial, repeat, investigational

    Tumor-type agnostic solid tumor molecular profiling panels are covered for specified diagnoses and repeat testing in select progressions.

    Initial coverage: Covered when the member has one of the listed tumor diagnoses (recurrent/relapsed/refractory/metastatic/advanced stage III-IV cancer; histiocytosis; NSCLC any stage; resectable/borderline resectable pancreatic adenocarcinoma; CNS tumor) AND the member is seeking further cancer treatment, OR for initial evaluation of uterine neoplasm, OR for GIST negative for KIT/PDGFRA.

    Codes include 0037U, 0048U, 0250U, 0329U, 0334U, 0379U, 0391U, 0473U, 81445, 81455, 81457, 81458, 81459

    Repeat testing coverage: Repeat testing via listed tumor-type agnostic panels is medically necessary when the member has progression of advanced/metastatic NSCLC, advanced/metastatic gastric adenocarcinoma, or metastatic prostate cancer.

    Repeat-testing codes same as initial

    Investigational for other indications: These tumor-type agnostic panels are investigational for indications not explicitly listed above.

    Targeted RNA fusion panels

    RNA specific fusion panels (81449) are covered for specific hematologic and solid tumor indications or when DNA testing is negative for actionable findings.

    Covered diagnoses: Member has ALL, glioma, histiocytosis, sarcoma; OR member has GIST negative for KIT/PDGFRA; OR member has NSCLC with negative DNA-based NGS for actionable mutations; OR member has metastatic/advanced solid tumor with an approved fusion-targeted therapy OR DNA-based panel negative for oncogenic drivers.

    81449

    Investigational for other indications: 81449 is investigational for all other indications.

    Broad RNA fusion panels

    Broad RNA fusion panels using RNA analysis alone (0444U, 81456) are restricted to ALL.

    Covered indication: Member has a diagnosis of adult or pediatric acute lymphoblastic leukemia (ALL).

    0444U, 81456

    Investigational for other indications: These broad RNA fusion panels are investigational for all other indications.

    Broad hematologic/myeloid panels

    Broad hematologic panels (81450, 81455) are covered for initial evaluation and specific scenarios; repeat testing covered for relapse/progression contexts.

    Initial coverage: Covered when evaluating AML; newly diagnosed ALL; newly diagnosed MDS; suspected MDS after other causes of cytopenia ruled out; suspected MPN as initial genetic evaluation or after negative JAK2/CALR/MPL testing; or CML with progression to accelerated/blast phase.

    81450, 81455

    Repeat testing coverage: Repeat testing is medically necessary for MDS relapsed after allo-HCT; ALL with symptomatic relapse after maintenance; AML with relapsed/refractory disease or progression on treatment.

    81450, 81455

    Investigational for other indications: These panels are investigational for all other indications.

    Colorectal cancer-focused panels

    Colorectal-focused panels (81445, 81457) are covered only for metastatic disease and must include specific genes.

    Coverage criteria: Member has suspected or proven metastatic colorectal cancer AND the panel contains at minimum KRAS, NRAS, and BRAF.

    81445, 81457

    Investigational for other indications: These panels are investigational for all other indications.

    Lung cancer-focused panels

    Lung-focused panels (0022U, 81457) are covered for advanced/metastatic lung cancers when further cancer treatment is being sought; repeat testing covered upon progression on targeted therapy.

    Coverage criteria: Member has advanced (stage IIIb or higher) or metastatic lung adenocarcinoma, large cell lung carcinoma, squamous cell lung carcinoma, or NSCLC NOS AND is seeking further cancer treatment.

    0022U, 81457

    Repeat testing: Repeat lung-focused panels are medically necessary when there is progression on targeted therapy for NSCLC.

    0022U, 81457

    Investigational for other indications: Lung-focused panels are investigational for all other indications.

    Cutaneous melanoma-focused panels

    Cutaneous melanoma panels (81445, 81457) are covered for stage III or higher, recurrent melanoma when seeking further cancer treatment and meeting prior testing conditions.

    Coverage criteria: Member has stage III or higher or recurrent melanoma AND is seeking further cancer treatment AND either has not had previous somatic multigene testing for the same primary melanoma or has a new primary melanoma after prior testing.

    81445, 81457

    Investigational for other indications: These panels are investigational for all other indications.

    Acute Myeloid Leukemia focused panels

    AML focused panels (0050U, 81450) are covered for suspected or confirmed AML.

    Coverage criteria: Member has suspected or confirmed acute myeloid leukemia (AML).

    0050U, 81450

    Investigational: AML focused panels are investigational for indications other than AML diagnosis/evaluation.

    Myeloproliferative neoplasm panels

    MPN molecular profiling panels are covered for suspected MPN when panel includes minimum genes.

    Coverage criteria: Member is suspected to have a myeloproliferative neoplasm AND the panel includes at minimum JAK2, CALR, and MPL.

    Codes include 81206, 81207, 81208, 81219, 81270, 81279, 81338, 81339

    Investigational for other indications: MPN panels are investigational for all other indications.

    Tumor-specific variant analyses coverage

    Specific variant tests are covered when associated with the listed diagnoses or clinical scenarios.

    BCR-ABL1 kinase domain (81170): Covered for CML or Ph-positive ALL when inadequate initial response, loss of response to TKI, progression to accelerated/blast phase, or relapsed/refractory disease.
    BCR-ABL1 FISH/qual/quant: Covered when suspected MPN or during diagnostic workup for ALL, AML, CML, B-cell lymphoma, or for MRD monitoring (quantitative only) in ALL, AML, CML, B-cell lymphoma.
    BRAF (81210): Covered for listed solid tumor diagnoses including metastatic colorectal cancer, advanced/metastatic NSCLC, stage III/IV cutaneous melanoma, selected thyroid cancers, select gliomas, pancreatic adenocarcinoma, small bowel adenocarcinoma, and advanced gastric/esophageal cancers; also select hematologic indications like hairy cell leukemia and histiocytosis.
    BRCA1/2 tumor testing: Covered for ovarian/fallopian tube/primary peritoneal cancer, metastatic prostate cancer, and resectable/borderline resectable/locally advanced/metastatic pancreatic cancer.

    Tumor Specific IDH1 and IDH2 Variant Analysis

    Covered when ANY of the following diagnoses are present

    Diagnoses for IDH1/2: Glioma OR Acute myeloid leukemia (AML)

    Tumor Specific IGHV Somatic Hypermutation Analysis

    Covered when ANY of the following hematologic diagnoses are present

    Diagnoses for IGHV: Chronic lymphocytic leukemia (CLL) OR Small lymphocytic leukemia (SLL) OR Primary cutaneous B-cell lymphoma OR B-cell lymphoma

    Tumor Specific JAK2 Variant Analysis

    Covered when ANY of the following are present

    Indications for JAK2 testing: Suspected myeloproliferative neoplasm (MPN) OR Acute lymphoblastic leukemia (ALL) OR Suspected myelodysplastic syndrome (MDS)

    Tumor Specific KIT Variant Analysis

    Covered when ANY of the following evaluation or diagnoses are present

    Indications for KIT testing: Evaluation for systemic mastocytosis OR Acute myeloid leukemia (AML) OR Stage IV cutaneous melanoma OR Suspected/confirmed GIST

    Tumor Specific KRAS Variant Analysis

    Covered when ANY of the following solid tumor contexts are present

    Indications for KRAS testing: Suspected/proven metastatic colorectal cancer OR Workup for NSCLC metastasis OR Resectable/borderline/locally advanced/metastatic pancreatic adenocarcinoma OR Unresectable/metastatic gallbladder cancer OR Unresectable/metastatic intrahepatic or extrahepatic cholangiocarcinoma

    Tumor Specific MGMT Methylation Analysis

    Covered when ALL of the following are met

    MGMT indications: Diagnosis of high grade (stage III or IV) anaplastic oligodendroglioma OR anaplastic astrocytoma OR anaplastic glioma OR glioblastomaHigh grade (stage III or IV)

    Tumor Specific MLH1 Methylation Analysis

    Covered when BOTH conditions are met

    MLH1 methylation prerequisites: Diagnosis of colorectal cancer OR endometrial (uterine) cancer AND prior tumor testing showed loss of MLH1 on immunohistochemistry

    Tumor Specific MPL Variant Analysis

    Covered when ANY of the following are present

    Indications for MPL testing: Suspected myeloproliferative neoplasm (MPN) OR Suspected myelodysplastic syndrome (MDS)

    Tumor Specific Microsatellite Instability (MSI) Analysis

    Covered when the member has any of the listed solid tumor diagnoses

    MSI-covered tumor types: Colorectal cancer OR Endometrial cancer OR Gastric cancer OR Esophageal/EGJ cancer OR Recurrent/progressive/metastatic cervical carcinoma OR Testicular cancer after high-dose/third-line chemo OR Unresectable/metastatic gallbladder OR Unresectable/metastatic cholangiocarcinoma OR Unresectable/metastatic breast cancer OR Small bowel adenocarcinoma OR Resectable/borderline/metastatic pancreatic cancer OR Metastatic occult primary OR Recurrent/progressive/metastatic vulvar squamous cell carcinoma OR Metastatic chondrosarcoma OR Metastatic chordoma OR Widely metastatic Ewing sarcoma OR Metastatic osteosarcoma OR Recurrent/metastatic vaginal cancer OR Recurrent ovarian cancer

    CPT 81301

    Tumor Specific NRAS Variant Analysis

    Covered when ANY of the following are present

    NRAS indication: Suspected or proven metastatic colorectal cancer

    Tumor Specific NPM1 Variant Analysis

    Covered when the following is present

    NPM1 indication: Cytogenetically normal acute myeloid leukemia (AML)

    Tumor Specific PIK3CA Variant Analysis

    Covered when the following is present

    PIK3CA indication: Recurrent or stage IV, HR-positive, HER2-negative invasive breast cancer

    Tumor Specific TP53 Variant Analysis

    Covered when ANY of the following hematologic diagnoses or workup contexts are present

    TP53 indications: Acute myeloid leukemia (AML) OR Chronic lymphocytic leukemia (CLL) OR Small lymphocytic leukemia (SLL) OR Undergoing diagnostic workup for mantle cell lymphoma (MCL)

    HLA Typing for Transplantation

    Covered when ALL of the following relate to transplantation

    HLA transplant indications: Being considered as recipient or donor for bone marrow transplantation OR recipient or donor for solid organ transplantation

    CPT 81370-81382; HLA typing investigational for all other indications

    Hematologic Minimal Residual Disease (MRD) Testing

    Covered when ANY of the following hematologic diagnoses are present

    Hematologic MRD indications: Acute Lymphocytic Leukemia (ALL) OR Multiple Myeloma OR Chronic Lymphocytic Leukemia (CLL)

    Codes 0171U, 0364U

    Evidence-Based Solid Tumor Minimal Residual Disease (MRD) Testing

    Covered when ALL of the following are met

    Evidence-based cfDNA MRD general criteria: (A) Identification of recurrent, refractory, or progressive disease will require a change in management AND (B) Member is not undergoing concurrent molecular laboratory testing for surveillance/monitoring AND (C) Member meets one of the listed clinical contexts (currently being treated with test not previously done OR not currently treated with test not done in past 12 months or clinical suspicion for recurrence) AND (D) Member meets a test-specific indication (Guardant360 Response/Reveal for colon cancer monitoring or Signatera for specified cancers or any solid tumor being monitored for response to immune checkpoint inhibitor therapy)

    Codes 0340U, 0422U, 81479; specific test and cancer-type combinations required

    HPV-Related Solid Tumor Minimal Residual Disease (MRD) Testing

    Covered when ALL of the following are met

    HPV-related MRD criteria: Personal history of HPV-driven oropharyngeal cancer AND identification of recurrence/progression will require change in management AND not undergoing concurrent surveillance by other method AND meets one of listed clinical timing contexts (e.g., currently being treated)

    Code 0356U

    Emerging Evidence Solid Tumor MRD Testing

    Not covered (investigational) when the assays have insufficient evidence of clinical validity

    Emerging MRD assays investigational: Minimal residual disease analysis with insufficient evidence of clinical validity using solid tumor tissue (codes 0229U, 0306U, 0307U)

    HPV-Related Solid Tumor MRD Testing (cell-free DNA, 0356U)

    Medically necessary when ALL of the following are met:

    HPV-related MRD eligibility: Member has a personal history of HPV-driven oropharyngeal cancer; identification of recurrence or progression will require a change in management; member is not undergoing concurrent surveillance by any other method; member meets one of the following treatment status criteria

    cell-free DNA MRD (0356U)

    Tumor Mutational Burden (81479)

    Considered medically necessary when ALL of the following are met:

    TMB eligibility: Member has recurrent, relapsed, refractory, metastatic, or advanced stage III or IV cancer; had progression following prior treatment; has no remaining satisfactory treatment options; does not have central nervous system cancer

    TMB testing (81479) criteria

    Red Blood Cell Genotyping in Multiple Myeloma (0001U, 0180U, 0221U)

    Considered medically necessary when ALL of the following are met:

    RBC genotyping eligibility: Member has diagnosis of multiple myeloma; member is currently being treated or will be treated with daratumumab or isatuximab; test has not previously been done for this episode of cancer OR the test has not been done in the past 12 months

    RBC genotyping coverage conditions

    Cancer Exome and Genome Sequencing

    Coverage stance:

    Exome/genome sequencing: Cancer exome and genome sequencing in solid tumors and hematologic malignancies is considered investigational

    Codes: 0036U, 0297U, 81415, 81416, 81425, 81426

    Non-Small Cell Lung Cancer

    Covered when consistent with guideline-recommended indications (examples below by tumor type and gene):

    NSCLC molecular testing: Molecular testing for advanced or metastatic NSCLC is recommended; broad panel-based NGS preferred; test for EGFR and ALK also recommended for stages IB-IIIA or IIIB[T3,N2] if perioperative systemic therapy is considered.

    Cutaneous Melanoma

    Covered when guideline-indicated for melanoma staging and therapeutic decisions:

    Melanoma BRAF/KIT testing: BRAF testing recommended for stage III disease; KIT testing for stage IV disease or clinical recurrence; broader profiling considered if results may guide treatment or trial eligibility; repeat testing after progression on targeted therapy generally not useful.

    AML, MPN, CML, ALL molecular testing

    Hematologic malignancy panels recommended for diagnosis, prognostication, and therapy selection:

    AML molecular panel: Multiplex NGS panels and targeted NGS recommended for adult AML patients for prognostication, therapy, and ongoing management; include genes such as FLT3, IDH1/IDH2, NPM1, CEBPA, RUNX1, ASXL1, TP53.
    MPN initial work-up: Molecular testing for JAK2 recommended in initial MPN work-up; if negative test MPL and CALR or use multigene NGS panel including JAK2, MPL, CALR as alternative.
    BCR::ABL1 testing in CML/ALL: Quantitative RT-PCR for BCR::ABL1 recommended for work-up and monitoring in CML; ABL1 kinase domain testing recommended for loss of response or progression and in relapsed/refractory Ph+ B-ALL.

    BRCA1/2 tumor testing

    BRCA1/2 tumor and germline testing recommendations:

    Ovarian BRCA testing: All patients with ovarian, fallopian tube, or primary peritoneal cancer should have germline BRCA1/2 testing; if negative for germline pathogenic variants, somatic tumor testing for BRCA1/2 should be performed to inform maintenance therapy.
    Prostate and pancreatic BRCA/HRR testing: Tumor testing for BRCA1/2 (and other HRR genes) recommended in metastatic prostate cancer and molecular profiling including BRCA1/2 recommended for pancreatic adenocarcinoma when systemic therapy is being considered.

    Breast cancer — ESR1

    ESR1 testing in breast cancer:

    ESR1 testing at progression: Testing for ESR1 mutations should occur at progression following endocrine therapy in ER-positive, HER2-negative patients after one or two lines of endocrine therapy (including a CDK4/6 inhibitor) to consider treatment with elacestrant.

    Tumor-specific IGHV analysis

    IGHV testing

    IGHV testing recommended per NCCN: NCCN recommends IGHV molecular testing for prognostic and/or therapy determination in CLL/SLL and recommends IGH gene rearrangement studies for B-cell lymphomas during diagnostic workup when adequate biopsy material is available.

    Tumor-specific JAK2 and MPL variant analysis

    JAK2/MPL/CALR testing for myeloproliferative and related disorders

    Initial MPN testing: Perform molecular testing for JAK2 in the initial workup for suspected MPN; if JAK2 negative, perform MPL and CALR testing or use multi-gene NGS panel including these genes.

    Tumor-specific KIT analysis

    KIT testing

    KIT testing in melanoma and GIST: Test for KIT mutations in stage IV or recurrent melanoma to guide treatment and to confirm KIT IHC; perform KIT mutation analysis for diagnosis and treatment selection in GIST.

    Tumor-specific KRAS/NRAS analysis

    RAS and related testing

    KRAS/NRAS testing in colorectal cancer: All patients with metastatic colorectal cancer should have tumor testing for RAS (KRAS and NRAS) and BRAF mutations individually or as part of NGS panel; testing can be done on primary tumor or metastasis.

    Tumor-specific MGMT methylation analysis

    MGMT promoter methylation testing

    MGMT methylation in high-grade gliomas: MGMT promoter methylation testing is recommended for all high-grade gliomas (grade 3 and 4) to assist risk stratification and treatment decisions.

    Tumor-specific MLH1 methylation analysis

    MLH1 methylation testing

    MLH1 tumor methylation when MLH1 IHC abnormal: For colorectal or endometrial cancers with abnormal MLH1 IHC, perform tumor MLH1 promoter methylation testing to evaluate for sporadic hypermethylation and guide need for germline Lynch testing.

    Tumor-specific MSI analysis

    MSI / MMR testing

    MSI testing across tumor types: NCCN recommends determination of tumor MMR or MSI for all newly diagnosed colorectal cancers and for many other tumor types (uterine, gastric, esophageal/EGJ, cervical progressive/recurrent/metastatic, biliary tract, recurrent/metastatic breast, small bowel adenocarcinoma, and others) as part of standard workup.

    Tumor-specific NPM1 and TP53 analysis

    AML and hematologic malignancy-associated genes

    NPM1 and TP53 testing in AML and hematologic malignancies: NCCN recommends molecular testing for genes including NPM1 and TP53 during evaluation for AML and for other hematologic malignancies where prognostic/treatment implications exist.

    Tumor-specific PIK3CA analysis

    PIK3CA testing in breast cancer

    PIK3CA in recurrent or stage IV HR+/HER2- breast cancer: Molecular testing for PIK3CA is recommended in patients with recurrent or stage IV HR-positive/HER2-negative breast cancers to identify candidates for PI3K-targeted therapy.

    MRD testing — covered when ALL criteria met

    MRD testing criteria

    MRD testing medical necessity per CMS MolDX: (1) Patient has personal history of cancer within intended use of the MRD test; (2) Identification of recurrence/progression would require a definitive change in management per NCCN or other guidelines; (3) The test demonstrates ability to detect molecular recurrence/progression before clinical/radiographic evidence and demonstrates sensitivity and specificity comparable to or better than standard monitoring methods.

    CMS MolDX LCD; NGS-based MRD tests generally allowed once per diagnosis unless genetic content changes.

    MRD medically necessary criteria

    Covered when ALL of the following are met

    MRD Coverage Criteria: 1) Patient has personal history of cancer within the intended use of the MRD test; 2) Identification of recurrence/progression is recognized by NCCN or other guidelines as requiring definitive change in management; 3) The test identifies molecular recurrence/progression before clinical/biological/radiographical evidence and demonstrates adequate sensitivity/specificity.

    Per CMS MolDX LCD; Concert default testing frequency when guidelines absent.

    MRD testing frequency

    Frequency rules

    MRD Frequency: Default frequency: once per cancer diagnosis for patients with cancer OR once every 12 months for patients without known cancer unless national/society guidelines specify otherwise.once per diagnosis or once every 12 months

    Tumor Mutational Burden (TMB)

    Coverage considerations for Tumor Mutational Burden (TMB) testing

    TMB Consideration: TMB testing is recommended or considered by NCCN in numerous tumor types to inform treatment choices including consideration of pembrolizumab where appropriate; FDA KEYTRUDA label uses TMB-H threshold >=10 mut/Mb and excludes CNS tumors.TMB-H >=10 mut/Mb

    Tumor-Type Agnostic Panels (revisions & expansions)

    Criteria expanded/minor expansions to align with updated NCCN guidelines; added several tumor types for coverage and specific CPT codes.

    Tumor-type agnostic panel coverage: Expanded criteria to include additional tumor types; CPT codes 81457-81459 added to criteria.

    Solid Tumor MRD (retired prior criteria; LCD-based sets)

    RETIRED prior MRD criteria; developed two new criteria sets based on LCD guidelines.

    Solid tumor MRD criteria set A: New LCD-based criteria set A governs coverage; CPT 0422U referenced.
    Solid tumor MRD criteria set B: New LCD-based criteria set B governs coverage; CPT 0422U referenced.

    Tumor Mutational Burden (TMB) revised coverage

    Coverage criteria revised to broader, tumor-agnostic eligibility consistent with NCCN.

    TMB coverage: Covered for any recurrent, refractory, metastatic, or advanced stage III or IV cancer (excluding CNS tumors) with progression on prior treatment and no satisfactory treatment options.

    RNA Fusion Panels coverage expansion

    Coverage expanded to include acute lymphoblastic leukemia and updated NCCN-guideline-based indications.

    Broad RNA Fusion Panels for ALL: Broad RNA fusion panels now covered for acute lymphoblastic leukemia per updated guidance.

    Updated and New Coverage Criteria (examples)

    Multiple updated and new criteria sets; examples include:

    MRD and related new criteria: New coverage criteria sets for HPV-related solid tumor MRD testing, Evidence-Based Solid Tumor MRD Testing, and Emerging Evidence Solid Tumor MRD Testing created; investigational criterion removed for HPV-related MRD.
    TMB coverage: TMB testing covered for any recurrent, refractory, metastatic, or advanced stage III or IV cancer (except CNS tumors) with progression on prior treatment and no satisfactory treatment options.
    Tumor-specific variant expansions: Coverage expanded for tumor-specific CEBPA variant analysis to all patients being evaluated for AML; ESR1 variant analysis expanded to include pre-menopausal women with ovarian ablation/suppression, postmenopausal women, and adult men.
    HLA typing: New criteria set for HLA typing for transplantation was created; investigational criterion removed to be consistent with the rest of the policy.

    Inclusion or exclusion of CPT/PLA/HCPCS codes, test names, or vendors in this policy is provided for informational and claims-navigation purposes only and does not guarantee coverage. Providers must verify coverage and coding guidance against current payer policies and the Concert platform prior to claim submission, and ensure submitted documentation supports medical necessity per the criteria in this policy.

    Tumor-type agnostic solid tumor molecular profiling panels and targeted RNA fusion panels (e.g., codes and examples listed in the criteria) are considered investigational and not covered for any indications other than those explicitly listed in the Coverage Criteria. Use of these panels for diagnoses or clinical scenarios not enumerated in the policy may be denied.

    Any application of multigene tumor panels, targeted RNA fusion panels, broad RNA fusion panels, or broad hematologic/myeloid panels that is described in the policy as 'investigational' or 'for all other indications' is excluded from coverage. Providers ordering these tests outside the listed covered indications should anticipate a potential denial and must document why the request meets coverage criteria if applicable.

    HLA typing (CPT codes 81370–81382 and related codes) is covered when performed for donor or recipient evaluation for hematopoietic stem cell or solid-organ transplantation. All other uses of HLA typing are designated investigational and not covered.

    Minimal residual disease (MRD) assays using solid tumor tissue or assays identified in this policy as having insufficient clinical validity (examples: 0229U, 0306U, 0307U) are considered investigational and not covered. Where MRD testing is proposed, coverage is contingent on meeting the CMS MolDX/LCD intended-use and performance criteria and documentation that detection of recurrence would change management; default frequency rules (typically once per cancer diagnosis) apply when guidelines do not specify otherwise.

    Cancer whole-exome and whole-genome sequencing (PLA/CPT examples: 0036U, 0297U, 81415, 81416, 81425, 81426) are considered investigational and not covered for both solid tumors and hematologic malignancies as described in the policy.

    Billing Codes and Code Groups

    Tumor-Type Agnostic Solid Tumor Molecular Profiling Panelsmixed
    0037UTumor-Type Agnostic Solid Tumor Molecular Profiling Panels (example: FoundationOne CDx)
    0048UTumor-Type Agnostic Solid Tumor Molecular Profiling Panels (example: MSK-IMPACT)
    0250UTumor-Type Agnostic Solid Tumor Molecular Profiling Panels
    0329UAgnostic Solid Tumor Molecular Profiling Panels
    0334UTumor-Type Agnostic Solid Tumor Molecular Profiling Panels (example: Guardant360 TissueNext; PGDx elio tissue complete)
    0379UTumor-Type Agnostic Solid Tumor Molecular Profiling Panels (example: Solid Tumor Expanded Panel, Quest)
    0391UTumor-Type Agnostic Solid Tumor Molecular Profiling Panels (example: Strata Select)
    0473UTumor-Type Agnostic Solid Tumor Molecular Profiling Panels
    81445NGS multigene panel (example use for several panels listed)
    81455NGS multigene panel (example use)
    1–10 of 13
    1/2
    RNA Fusion Panelsmixed
    81449Targeted RNA fusion panels (example: Targeted Solid Tumor NGS Fusion Panel)
    81456Broad RNA fusion panels (example: Tempus xR Whole Transcriptome)
    0444UBroad RNA fusion panel (example: Aventa FusionPlus)
    Hematologic Malignancy Panelsmixed
    81450Broad molecular profiling panels for hematologic malignancies / myeloid panels (example: FoundationOne Heme)
    81455NGS panel code referenced for hematologic panels
    Tumor-type Focused Panels (lung, colorectal, melanoma)mixed
    0022UOncomine Dx Target Test (lung cancer focused)
    0478ULung HDPCR (lung cancer focused)
    81457Lung cancer focused panel (example: OnkoSight Advanced Lung Cancer NGS Panel)
    81445Colorectal or melanoma focused panels (examples listed)
    81457Melanoma focused panel (example: OnkoSight Advanced Melanoma NGS Panel)
    Tumor-specific and Hematologic Variant and Fusion Testingmixed
    0050UAML focused molecular profiling (MyAML NGS Gene Panel Assay)
    81450AML/myeloid panels (examples: NeoTYPE AML Prognostic Profile, LeukoVantage)
    81206JAK2 V617F testing (component of MPN panels)
    81207JAK2/CALR/MPL related testing codes (used in MPN panels)
    81218CEBPA mutation analysis
    81219CALR mutation analysis
    81170ABL1 kinase domain mutation analysis
    81235EGFR mutation analysis
    81162BRCA1/2 mutation analysis (tumor)
    81163BRCA1/2 mutation analysis (tumor)
    1–10 of 26
    1/3
    Tumor-specific single-gene/variant CPT codesCPT
    81210BRAF Variant Analysis
    81162BRCA1/2 Mutation Analysis (various levels)
    81163BRCA1/2 Mutation Analysis (various levels)
    81164BRCA1/2 Mutation Analysis (various levels)
    81165BRCA1/2 Mutation Analysis (various levels)
    81166BRCA1/2 Mutation Analysis (various levels)
    81167BRCA1/2 Mutation Analysis (various levels)
    81216BRCA1/2 Mutation Analysis
    81219CALR Variant Analysis
    81218CEBPA Variant Analysis
    1–10 of 14
    1/2
    Additional single-gene and PLA codesmixed
    0023ULeukoStrat CDx FLT3 Mutation Assay
    0046UFLT3 ITD MRD Assay
    81120IDH1 Mutation Analysis
    81121IDH2 Mutation Analysis
    0481UIDH1/IDH2/TERT NGS Tumor
    81261IGHV/IgVH Somatic Mutation Analysis
    81262IGHV/IgVH Somatic Mutation Analysis
    81263IGHV/IgVH Somatic Mutation Analysis
    Hemato-oncology and tumor methylation/canonical gene codesmixed
    81270JAK2 V617F Mutation Analysis
    0017UJAK2 Mutation (platform-specific PLA)
    0027UJAK2 Exon 12-15 Sequencing
    81272KIT Mutation Analysis
    81273KIT Mutation Analysis
    81275KRAS Mutation Analysis
    81276KRAS Mutation Analysis
    81287MGMT Promoter Methylation Analysis
    81288MLH1 Promoter Methylation Analysis
    MSI, MRD, and additional mutation analysis codesCPT
    81301Microsatellite Instability (MSI) by PCR
    0049UNPM1 MRD Assay
    81310NPM1 Sequencing
    81311NRAS Mutation Analysis
    81309PIK3CA Variant Analysis
    81352TP53 Mutation Analysis
    HLA/transplantation codesCPT
    81370HLA Typing for Transplantation (various resolutions)
    81371HLA Typing
    81372HLA Typing
    81373HLA Typing
    81376HLA-DQB1,DQA1 Intermediate Resolution
    81378HLA A,B,C,DRB1 and DQ High Resolution
    81379HLA A,B,C Profile (High Resolution)
    81380HLA A High Resolution
    81382HLA High Resolution Panel by NGS
    MRD and cfDNA monitoring PLA/HCPCS codesmixed
    0171UMyMRD NGS Panel Assay (hematologic MRD)
    0364UClonoSEQ Assay (Adaptive Biotechnologies)
    0340USignatera MRD Test (Natera)
    0422UGuardant360 Response (Guardant Health) MRD
    0229UCOLVERA (emerging MRD)
    0306UInvitae Personalized Cancer Monitoring - Baseline Test (emerging)
    0307UInvitae Personalized Cancer Monitoring - Monitoring Test (emerging)
    0486UNorthstar Response (BillionToOne) (emerging)
    Emerging and specific MRD/TMB codesmixed
    0356UNavDx (Naveris) HPV-related MRD
    81479Tumor Mutational Burden (MedFusion) listed under 81479
    0340USignatera (repeated)
    Tumor-type agnostic panel and RNA fusion panel codesmixedCovered
    0037UTumor-type agnostic solid tumor molecular profiling panel (PLA)
    0048UTumor-type agnostic panel (PLA)
    0250UTumor-type agnostic panel (PLA)
    0329UTumor-type agnostic panel (PLA)
    0334UTumor-type agnostic panel (PLA)
    0379UTumor-type agnostic panel (PLA)
    0391UTumor-type agnostic panel (PLA)
    0473UTumor-type agnostic panel (PLA)
    81445Oncology multigene panel, tumor-type agnostic
    81455Oncology multigene panel
    1–10 of 14
    1/2
    Tumor-type agnostic and multi-gene panel codesmixed
    0037Ulisted tumor-type agnostic panel
    0048Ulisted tumor-type agnostic panel
    0250Ulisted tumor-type agnostic panel
    0329Ulisted tumor-type agnostic panel
    0334Ulisted tumor-type agnostic panel
    0379Ulisted tumor-type agnostic panel
    0391Ulisted tumor-type agnostic panel
    0473Ulisted tumor-type agnostic panel
    81445tumor-type agnostic / focused panel
    81455tumor-type agnostic / hematologic panel
    1–10 of 13
    1/2
    Targeted RNA fusion panel codesCPTCovered
    81449Targeted RNA fusion panels (5-50 genes)
    Broad RNA fusion panel codesCPT
    0444UBroad RNA fusion panel (51+ genes)
    81456Broad RNA fusion panel (51+ genes)
    Broad hematologic panel codesCPTCovered
    81450Broad molecular profiling panels for hematologic malignancies / myeloid malignancy panels
    Other focused panel / panel-specific codesCPTCovered
    0022ULung cancer focused molecular profiling panel
    0050UAML focused molecular profiling panel
    0023UFLT3 variant analysis
    0046UFLT3 variant analysis
    Tumor-specific single-gene and related codesmixedCovered
    81170Tumor specific BCR/ABL1 kinase domain analysis
    0016UTumor specific BCR/ABL1 FISH/qual/quant
    0040UTumor specific BCR/ABL1 FISH/qual/quant
    81206MPN / BCR/ABL1 related test
    81207MPN / BCR/ABL1 related test
    81208MPN / BCR/ABL1 related test
    81479ESR1 variant analysis
    88271Cytogenetic/FISH code
    88274Cytogenetic/FISH code
    88275Cytogenetic/FISH code
    1–10 of 26
    1/3
    Tumor-specific IDH1/IDH2CPTCovered
    81120Tumor specific IDH1 variant analysis
    81121Tumor specific IDH2 variant analysis
    Tumor-specific IGHVCPTCovered
    81261Tumor specific IGHV somatic hypermutation analysis
    81262Tumor specific IGHV somatic hypermutation analysis
    81263Tumor specific IGHV somatic hypermutation analysis
    Tumor-specific JAK2mixedCovered
    0017UJAK2 variant analysis (panel/unit)
    0027UJAK2 variant analysis (panel/unit)
    81270JAK2 variant analysis
    Tumor-specific KITCPTCovered
    81272KIT variant analysis
    81273KIT variant analysis
    Tumor-specific KRASCPTCovered
    81275KRAS variant analysis
    81276KRAS variant analysis
    Tumor-specific MGMT methylationCPTCovered
    81287MGMT promoter methylation analysis
    Tumor-specific MLH1 methylationCPTCovered
    81288MLH1 promoter methylation analysis
    Tumor-specific MPLCPTCovered
    81338MPL variant analysis
    81339MPL variant analysis
    Tumor-specific MSICPTCovered
    81301Microsatellite instability (MSI) analysis
    Tumor-specific NRASCPTCovered
    81311NRAS variant analysis
    Tumor-specific NPM1mixedCovered
    0049UNPM1 variant analysis (unit)
    81310NPM1 variant analysis
    Tumor-specific PIK3CAmixedCovered
    0155UPIK3CA variant analysis
    81309PIK3CA variant analysis
    Tumor-specific TP53CPTCovered
    81352TP53 variant analysis
    HLA Typing for TransplantationCPT
    81370HLA typing
    81371HLA typing
    81372HLA typing
    81373HLA typing
    81376HLA typing
    81378HLA typing
    81379HLA typing
    81380HLA typing
    81382HLA typing
    Hematologic MRDmixedCovered
    0171UHematologic MRD analysis
    0364UHematologic MRD analysis
    Evidence-based cfDNA MRDmixed
    0340UcfDNA MRD assay (evidence-based)
    0422UcfDNA MRD assay (evidence-based)
    81479Targeted sequencing assay (MRD)
    Emerging evidence MRD (investigational)mixedExperimental
    0229UEmerging/insufficient evidence MRD assay
    0306UEmerging/insufficient evidence MRD assay
    0307UEmerging/insufficient evidence MRD assay
    HPV-related cfDNA MRDCPT
    0356UcfDNA MRD for HPV-related head and neck cancer
    Emerging Evidence Solid Tumor MRD (investigational)CPTNot Covered
    0229UMRD analysis (solid tumor) - listed as investigational
    0306UMRD analysis (solid tumor) - listed as investigational
    0307UMRD analysis (solid tumor) - listed as investigational
    HPV-related MRD (covered with criteria)CPTCovered
    0356UCell-free DNA MRD testing for HPV-related oropharyngeal cancer (medically necessary with conditions)
    Tumor Mutational Burden (TMB)CPTCovered
    81479Tumor mutational burden (TMB) testing

    Covered Indications and Use Cases

    Provider Requirements, Prior Authorization, and Documentation

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for multiple services referenced in this policy. Submission of a prior authorization request must include clinical rationale, intended use, and supporting documentation as detailed below. Inclusion of CPT/PLA/GSP codes in this policy does not guarantee coverage — providers must obtain prior authorization when indicated and adhere to plan terms, exclusions, and documentation requirements. Investigational indications and services that do not meet medical necessity criteria may be denied.

    • Prior authorization required for evidence-based cfDNA MRD tests (e.g., 0229U, 0306U, 0307U, 0340U, 0422U) when meeting LCD/plan criteria.
    • Prior authorization required for HPV-related MRD (0356U) when criteria are met.
    • Prior authorization required for red blood cell (RBC) genotyping tests (0001U, 0180U, 0221U) in multiple myeloma when criteria are met.
    • Prior authorization required for molecular profiling panels (including tumor-type agnostic panels and newly referenced CPT codes 81457, 81458, 81459, and PLA/unique CPTs such as 0422U).
    • Prior authorization expectations: decision-making will follow submitted clinical documentation and adherence to evidence-based guidelines; incomplete documentation may delay or result in denial.

    Investigational and Not Covered Services

    Any use of a tumor-type agnostic multigene panel or an RNA fusion panel for a clinical indication that is not explicitly enumerated in the Coverage Criteria section is considered investigational and not covered. Providers must confirm that the requested indication matches one of the specific covered scenarios in the policy before ordering or submitting claims.

    Tumor profiling panels and RNA fusion tests identified as investigational in this policy are not covered when ordered for indications not listed among the covered criteria. This includes broad RNA fusion panels and multigene platform tests when the requested clinical use falls outside the defined covered diagnoses or monitoring contexts.

    Certain MRD assays using solid tumor tissue (notably codes 0229U, 0306U, 0307U) and other MRD tests lacking established clinical validity are designated as investigational and not covered. Coverage decisions for MRD testing depend on demonstration of clinical validity/utility per Concert policy and referenced third‑party technology assessments or CMS MolDX LCDs.

    Cancer exome and genome sequencing services and genetic tests billed solely to confirm specimen identity (where billed separately) are considered investigational and not covered. Providers should not bill these services as covered items unless the request clearly meets coverage criteria documented in this policy.

    Repeat tumor testing using the same testing approach after progression on a targeted therapy (for example, repeating BRAF‑ or KIT‑directed testing without a change in intended use) generally lacks demonstrated clinical utility and is not supported by this policy.

    Coverage for NGS‑based MRD assays and other molecular tests depends on the test’s intended use and evidence of clinical validity and utility. Tests validated only for specific tumor types or purposes may not be covered for other indications; providers must document that the proposed use aligns with the test’s validated intended use and policy criteria.

    Background and Definitions

    Background: Somatic molecular analysis of tumors identifies driver mutations, gene fusions, tumor mutational burden (TMB), and microsatellite instability (MSI) that inform targeted therapy selection, prognosis, diagnosis, and monitoring. Testing may be performed on tumor tissue, circulating tumor DNA (cell‑free DNA), blood, or bone marrow depending on tumor type and clinical context; results can guide therapeutic decisions and MRD surveillance, and somatic testing may reveal incidental germline findings requiring follow‑up.

    Definition — Somatic genomic profiling
    DefinitionSomatic genomic profiling: simultaneous evaluation of many genetic markers in tumor tissue to identify somatic oncogenic mutations that inform targeted therapy and prognosis
    Specimen typesPerformed on tumor tissue or via circulating tumor DNA/CTCs; hematologic malignancy testing may use blood or bone marrow
    Clinical purposesUsed for diagnosis, prognostication, treatment selection, and identifying potential incidental germline findings
    Definition — Tumor characteristics (TMB, MSI, fusions)

    Policy Revision History

    11/2024policy_revisionLatest

    Comprehensive policy revision incorporating multiple material changes: added Solid Tumor MRD testing criteria (including CPT 0422U), expanded Tumor Mutational Burden (TMB) coverage to broader tumor-agnostic indications consistent with NCCN and FDA TMB-H threshold, updated and added CPT/PLA codes (including 81457-81459), expanded tumor-specific coverage (e.g., CEBPA, ESR1), and retired prior MRD criteria replacing them with LCD-based sets.

    Material changes summarized: the policy added Solid Tumor MRD testing with LCD‑based criteria and default frequency guidance; Tumor Mutational Burden (TMB) criteria were broadened and updated to reference the FDA pembrolizumab TMB‑H threshold (≥10 mut/Mb); multiple CPT/HCPCS and proprietary code mappings were changed or added (including addition of CPTs 81457–81459 for tumor‑type agnostic panels and 0422U for Solid Tumor MRD); and several tumor‑specific coverage criteria were expanded to align with updated NCCN guidance (examples: CEBPA, ESR1). Providers should review the policy revision notes and updated code table when ordering or authorizing tests.

    Policy Summary
    PayerCommunity Health Plan Washington
    PolicyMolecular Analysis of Solid Tumors and Hematologic Malignancies (coverage criteria)
    Policy CodePolicy N/A
    Change TypeMaterial updates to MRD, TMB, coding, and tumor-specific criteria
    Effective DateN/A
    Last ReviewNov 20, 2024
    Next Review DateNov 1, 2025
    Key ActionObtain prior authorization and document diagnosis, prior testing, and that results will change management when ordering listed panels or MRD/TMB testing.
    SourceLink
    On This Page
    Coverage Criteria and Medical NecessityBilling Codes and Code GroupsCovered Indications and Use CasesProvider Requirements, Prior Authorization, and DocumentationInvestigational and Not Covered ServicesBackground and DefinitionsPolicy Revision History
    RNA-specific fusion panels (81449) are investigational for all other indications
    CALR (81219): Covered when suspected MPN or suspected MDS.
    CEBPA (81218): Covered when undergoing evaluation for AML.
    EGFR (81235): Covered for stage IB or higher lung adenocarcinoma, large cell lung carcinoma, squamous cell lung carcinoma, or NSCLC NOS.
    ESR1 (81479): Covered for ER-positive, HER2-negative breast cancer in specified patient groups with disease progression after one or two prior lines of endocrine therapy including one with a CDK4/6 inhibitor.
    FLT3 (0023U, 0046U, 81245, 81246): Covered for suspected or confirmed AML, or diagnosis of ALL, MDS, or MPN.
    IDH1/IDH2 (81120, 81121): Covered for glioma or AML.
    Red Blood Cell Genotyping (covered with criteria)CPTCovered
    0001URed blood cell genotyping (multiple myeloma)
    0180URed blood cell genotyping (multiple myeloma)
    0221URed blood cell genotyping (multiple myeloma)
    Cancer Exome and Genome SequencingmixedNot Covered
    0036UCancer exome sequencing (investigational)
    0297UCancer genome sequencing (investigational)
    81415Exome/genome sequencing (investigational)
    81416Exome/genome sequencing (investigational)
    81425Exome/genome sequencing (investigational)
    81426Exome/genome sequencing (investigational)
    Genetic testing to confirm specimen identityCPTNot Covered
    81265Genetic testing to confirm sample identity (investigational when billed separately)
    81266Genetic testing to confirm sample identity (investigational when billed separately)
    81479Also referenced in specimen identity context
    Tumor-specific BCR/ABL1 qualitative and quantitative testsmixed
    not providedRT-PCR quantitative or qualitative testing for BCR::ABL1; MRD monitoring
    Tumor-specific gene variant analyses (BRAF, BRCA1/2, EGFR, etc.)mixed
    not providedBRAF variant analysis (includes V600E and fusions)
    not providedBRCA1/2 tumor (somatic) testing
    not providedEGFR variant analysis
    MPN-related gene testing (JAK2, CALR, MPL)mixed
    not providedCALR and JAK2 variant analysis
    AML-related gene testingmixed
    not providedFLT3 and IDH1/IDH2 variant analysis
    Lymphoid clonality and prognostic testingmixed
    not providedIGHV somatic hypermutation and Ig gene rearrangement studies
    Updated/added procedure and proprietary codes referenced in revisionsmixed
    0379UProprietary test code added to policy tables
    0297UReplaced prior code 0329U in cancer exome/genome sequencing
    81455Replaced 81449 in multiple table entries
    0250UAdded in place of removed codes in tumor-type agnostic panels
    81352Added under TP53 variant analysis
    81279Added for Myeloproliferative Neoplasms (MPNs) panel tests
    Policy reference CPT/HCPCS changesCPT
    0297UReplaced 0329U in Cancer Exome and Genome Sequencing
    0329UReplaced (old) — removed and replaced with 0297U
    0422UAdded to policy reference table and criteria for Solid Tumor MRD Testing
    81457Added to criteria for Tumor-Type Agnostic Solid Tumor Molecular Profiling Panel Tests
    81458Added to criteria for Tumor-Type Agnostic Solid Tumor Molecular Profiling Panel Tests
    81459Added to criteria for Tumor-Type Agnostic Solid Tumor Molecular Profiling Panel Tests
    0079URemoved from Genetic Testing to Confirm the Identity of Laboratory Specimens
    Covered CPT CodesCPT
    No codes listed
    Relevant LCD/CMS articlesmixed
    No codes listed
    Coding: None specified
    Coding key listNone specified
    Panel gene count (tumor-type agnostic)
    Panel definitionTumor-type agnostic panels identified by listed PLA/CPT codes (e.g., 0037U, 0048U, 0250U, 0329U, 0334U, 0379U, 0391U, 0473U, 81445, 81455, 81457-81459)
    Typical useUsed across tumor types to identify actionable alterations for treatment selection in specified diagnoses (advanced/metastatic/recurrent/relapsed/refractory cancers, NSCLC any stage, resectable pancreatic adenocarcinoma, CNS tumors, initial uterine neoplasm evaluation, GIST negative for KIT/PDGFRA)
    Repeat testing ruleRepeat testing medically necessary for progression of advanced/metastatic NSCLC, advanced/metastatic gastric adenocarcinoma, or metastatic prostate cancer
    RNA fusion panel gene count (broad = 51+ genes)
    Broad RNA fusion panel sizeBroad RNA fusion panels utilize RNA analysis alone and include 51 or more genes (examples: 0444U, 81456)
    Covered indication (broad panels)Covered only for adult or pediatric acute lymphoblastic leukemia (ALL)
    Investigational for othersBroad RNA fusion panels (51+ genes) are investigational for all other indications
    MGMT relevant tumor grade
    Relevant tumor gradeMGMT promoter methylation testing is indicated for high-grade tumors (stage III or IV) such as anaplastic oligodendroglioma, anaplastic astrocytoma, anaplastic glioma, and glioblastoma
    Intended useUsed for risk stratification and treatment decisions in high-grade gliomas
    CPT exampleCPT 81287
    TMB eligibility summary
    Eligibility — clinical statusMember has recurrent, relapsed, refractory, metastatic, or advanced stage III/IV cancer with progression after prior treatment and no satisfactory treatment options
    Exclusion — CNS tumorsTMB testing is excluded for central nervous system (CNS) cancers
    Documentation requirementDocumentation should support unresectable/metastatic disease and interpretation of TMB relative to FDA threshold when used to consider pembrolizumab
    MRD test frequency (operational default)
    Default frequency (with cancer)NGS-based MRD tests may be performed once per patient per cancer diagnosis unless there is clinical evidence of an a priori change in genetic content
    Default frequency (without known cancer)When patient is not known to have cancer, frequency follows national or society guidelines; absent guidance, default is once every 12 months
    Rationale sourceCMS MolDX LCD and billing/coding guidance referenced for intended-use and frequency rules
    TMB-H threshold
    TMB-H threshold>=10 mutations per megabase (mut/Mb) as defined by FDA for consideration of pembrolizumab
    ContextApplies for unresectable or metastatic solid tumors per FDA label; caution for pediatric/CNS tumors where effectiveness not established
    TMB coverage threshold (revised)
    Coverage threshold (revised)Covered for any recurrent, refractory, metastatic, or advanced stage III or IV cancer (excluding CNS tumors) with progression on prior treatment and no satisfactory treatment options
    Relation to FDA/NCCNRevisions align with NCCN guidance and incorporate FDA TMB-H threshold for pembrolizumab
    CPT exampleCPT 81479 for TMB testing
    Tumor stage for TMB coverage
    Covered tumor stagesRecurrent, refractory, metastatic, or advanced stage III or IV cancer (excluding CNS tumors)
    Required clinical conditionProgression after prior treatment with no satisfactory treatment options
    Not applicableCNS tumors are excluded from TMB coverage
    Prior Authorization

    MRD Prior Authorization and Frequency Limits

    MRD testing is subject to specific medical necessity criteria and frequency limits consistent with MolDX LCD guidance. For MRD tests that have demonstrated clinical validity and utility in the intended use population, prior authorization will evaluate whether the request meets LCD criteria for intended cancer type, whether identification of recurrence/progression would change management, and whether test performance is adequate relative to existing monitoring modalities. In the absence of clear guideline-directed frequency, the default frequency is once per cancer diagnosis; for patients without known cancer, the default frequency is once every 12 months.

    • MRD medical necessity and prior authorization headline reflects MolDX LCD criteria.
    • Default single-service limitation: MRD testing may be authorized once per cancer diagnosis unless clinical evidence supports additional testing (e.g., change in tumor genomics).
    • Requests for repeat MRD testing must document clinical evidence of change in disease status or treatment implications.
    • Investigational solid tumor MRD tests (including NGS-based assays without demonstrated clinical validity for the intended use) may be denied.
    • Newly referenced CPT 0422U has been added to MRD code lists and requires use on claims and authorization requests where applicable.
    Denial Risk

    Investigational Indications and Denial Risk

    Plan review of requests will consider investigational status and medical necessity. Tests and indications designated investigational in this policy (for example, cancer exome/genome sequencing outside defined criteria, specimen identity testing billed separately, and solid tumor MRD without demonstrated validity) are subject to denial. Coding inclusion is informational only and does not imply coverage — providers must justify clinical need in the prior authorization.

    • Investigational services may be denied if not supported by evidence-based guidelines or LCD criteria.
    • Solid tumor MRD testing using tissue or assays with insufficient evidence is considered investigational for specified indications and may be denied.
    • Specimen identity testing billed separately (e.g., 81265, 81266, 81479 when used for specimen ID) is considered investigational.
    • Coding inclusion is not a guarantee of coverage; providers should verify coverage and obtain prior authorization when required.
    Documentation Required

    Required Clinical Documentation

    Submit clinical documentation with all prior authorization requests. Documentation must clearly state the clinical rationale, intended use of the test, disease status, prior tests and results, current or planned therapies that would be affected by results, and any guideline references supporting testing. Use of specific panel codes requires documentation that the panel content matches the clinical question.

    • Required clinical documentation: diagnosis, stage, treatment history, prior molecular testing and results, and how results will change management.
    • Clinical rationale and intended use must be explicit (e.g., therapy selection, monitoring response, confirmation of diagnosis).
    • When requesting tumor-type agnostic panels or broad hematologic panels, specify which genes/fusions in the panel are needed and why.
    • Coding and documentation updates: use newly referenced CPT codes (e.g., 0422U, 81457-81459) on authorization requests and claims where applicable.
    Documentation Required

    Test-Specific Documentation Requirements

    Specific panel and test requests have additional documentation requirements; provide the following when applicable.

    • Colorectal panels (81445, 81457): document suspected or proven metastatic colorectal cancer and that panel includes at minimum KRAS, NRAS, and BRAF.
    • MPN panels (e.g., 81206, 81207, 81208, 81219, 81270, 81279, 81338, 81339): document suspicion of MPN and that JAK2, CALR, and MPL are included; stepwise testing is acceptable (e.g., JAK2 → CALR/MPL) and may be reflected in authorization requests.
    • MLH1 methylation (81288): prior tumor IHC demonstrating loss of MLH1 must be documented before methylation testing.
    • HPV-related MRD (0356U): document personal history of HPV-driven oropharyngeal cancer, that detection would change management, absence of concurrent surveillance by other methods, and timing relative to treatment; if using tumor tissue MRD, note investigational status when applicable.
    • TMB and RBC genotyping (81479; 0001U, 0180U, 0221U): for TMB, document prior progression and lack of satisfactory options per criteria; for RBC genotyping in multiple myeloma, document planned or ongoing treatment with daratumumab or isatuximab and that testing has not been performed for the current cancer episode or within the prior 12 months.
    • HLA typing (81370–81382): document transplant indication (recipient or donor for bone marrow or solid organ) and level of typing required per transplant program.
    • MRD documentation requirements: confirm cancer type is within intended use population of the test, provide guideline references showing that molecular detection would lead to definitive change in management, and provide evidence supporting test sensitivity/specificity for the indication.
    Billing Rule

    Coding, Billing, and Precedence

    Operational and coding notes to support authorization and claims processing.

    • When a multigene panel is performed, appropriate panel codes must be used; newly referenced CPT codes (81457, 81458, 81459 and 0422U) should be used on claims and authorization forms.
    • Coding inclusion in this policy is informational and does not imply automatic coverage — providers should obtain prior authorization and ensure documentation aligns with criteria.
    • If additional IHC or cytogenetic analyses accompany PLA or GSP codes, these may be billed alongside the panel with documentation supporting medical necessity.
    Step Therapy

    Stepwise Testing for MPN Genes

    For MPN gene testing a stepwise testing approach is an acceptable clinical pathway and may be reflected in authorization requests; if initial single-gene testing (e.g., JAK2) is negative, authorization can be requested for subsequent gene testing (CALR, MPL) or a broader NGS panel including all genes. Provide prior test results and rationale for progression to broader testing.

    • Stepwise testing option: JAK2 first, followed by CALR and MPL if negative, OR upfront multigene NGS panel including JAK2, CALR, MPL.
    • Authorization requests should include prior single-gene test results when applicable to justify stepwise escalation.
    Denial Risk

    Denial Risk for Nonconforming or Emerging Tests

    Providers should be aware that some services described in this policy are investigational or have limited evidence. Requests for such services should include strong clinical justification and references to supportive guidelines or technology assessments; absent that, the services may be denied.

    • Emerging or limited evidence tests may be denied unless robust evidence or guideline support is provided.
    • Changes to MRD or other criteria (e.g., addition of new CPTs) require use of updated codes and documentation consistent with current criteria.

    Tests that lack evidence demonstrating clinical validity or clinical utility as defined by Concert’s general genetic and molecular testing approach and associated technology assessments are considered not covered.

    The Praxis Extended RAS Panel (Illumina; code 0111U) has been removed from the policy reference table because it does not meet the minimum gene list required by the panel criteria; absence from the reference table should be interpreted as not meeting the policy’s panel definition.

    Emerging MRD assays for which clinical validity has not been established are addressed in a separate criteria set and are generally not covered outside the limited LCD‑supported indications. Providers should rely on the Evidence‑Based and HPV‑related MRD criteria (and the CMS MolDX LCDs cited) for allowed uses.

    DefinitionTumor characteristics: attributes such as tumor mutational burden (TMB), microsatellite instability (MSI), and gene fusions that can predict response to therapies including immunotherapy
    TMBMeasurement of mutations carried by tumor cells used as a predictive biomarker for immunotherapy response
    MSIMicrosatellite instability testing determines mismatch repair (MMR) status and is recommended universally in several cancers per NCCN
    Definition — Minimal Residual Disease (MRD)
    DefinitionMinimal Residual Disease (MRD): highly sensitive molecular assays used to detect low levels of tumor-derived DNA or cellular markers to monitor residual disease, recurrence, or response to therapy
    Intended usesDetection of recurrence/progression that would change management; monitoring response to therapy (test-specific indications apply)
    Frequency guidancePer MolDX LCD: generally once per cancer diagnosis unless clinical evidence warrants additional testing; specifics per test/guideline
    Definition — Tumor-type agnostic panel
    DefinitionTumor-type agnostic panel: broad NGS panels or platform-level tests that profile multiple genes across tumor types to identify actionable mutations for therapy selection
    ExamplesPLA/GSP/CPT codes listed in policy (e.g., 0037U, 0048U, 0250U, 0329U, 0334U, 0379U, 0391U, 0473U, 81445, 81455, 81457-81459)
    Coverage noteMedically necessary only for specified diagnoses and scenarios per policy criteria; investigational for other indications
    Definition — Tumor-type agnostic solid tumor molecular profiling panel
    DefinitionTumor-type agnostic solid tumor molecular profiling panel: comprehensive multigene tumor profiling panels used across tumor types to identify actionable alterations; medically necessary only for specified diagnoses or when seeking further cancer treatment
    CodesIncludes specific PLA/GSP and CPT codes listed in policy reference table
    Repeat testingRepeat-testing rules specified for selected progressions (see policy)
    Definition — RNA specific fusion panel
    DefinitionRNA specific fusion panel: panels using RNA to detect gene fusions (typically 5-50 genes; example CPT 81449) used for listed hematologic and solid tumor indications
    Typical indicationsCovered for ALL, glioma, histiocytosis, sarcoma, GIST negative for KIT/PDGFRA, NSCLC with negative DNA NGS, or metastatic/advanced solid tumors with fusion-targeted therapy or negative DNA panel
    Broad vs targetedTargeted RNA fusion panels (5-50 genes) differ from broad RNA panels (51+ genes) which have more limited coverage (e.g., ALL only)
    Definition — Minimal Residual Disease (MRD) for cfDNA/tissue
    DefinitionMRD for cfDNA/tissue: molecular analysis to detect residual tumor-derived DNA in blood (cell-free) or tissue to inform recurrence, progression, or response to therapy
    Test examplesSignatera (0340U), Guardant Reveal/Response (0422U), NavDx (0356U) with test-specific indications
    LCD requirementsCoverage depends on CMS MolDX LCD intended-use criteria including patient history, actionable change in management, and demonstrated clinical validity
    Definition — Tumor mutational burden
    DefinitionTumor mutational burden (TMB): a measurement of mutations carried by tumor cells used as a predictive biomarker for immunotherapy consideration
    Use caseTMB results may inform consideration of pembrolizumab per FDA label when TMB-H threshold is met
    MeasurementExpressed as mutations per megabase (mut/Mb)
    Definition — Advanced cancer
    DefinitionAdvanced cancer: cancer that is unlikely to be cured or controlled with treatment and may have spread regionally or distantly; often used to identify patients for tumor profiling and treatment selection
    ContextUsed in eligibility criteria for panels and TMB testing (advanced/metastatic/recurrent/refractory disease)
    Definition — Multiplex/NGS panel
    DefinitionMultiplex/NGS panel: next-generation sequencing-based multi-gene panels used to detect mutations, fusions, and other genomic alterations for prognosis and therapy selection
    ApplicationsRecommended in AML, MPN, NSCLC, and many other tumor types per NCCN guidance
    Definition — BCR::ABL1 testing
    DefinitionBCR::ABL1 testing: RT-PCR or FISH testing for BCR::ABL1 used for diagnosis and monitoring in CML and B-ALL, including quantitative RT-qPCR for MRD assessment
    UseRecommended for diagnostic workup and MRD monitoring per NCCN
    Definition — MRD (short)
    DefinitionMRD (short): minimal/measurable residual disease — molecular DNA/RNA assays to detect residual cancer post-treatment for monitoring recurrence or treatment response
    Intended-use noteCMS MolDX defines intended use and performance requirements for MRD assays
    Definition — MRD testing (detailed)
    DefinitionMRD testing (detailed): minimally invasive molecular DNA/RNA tests that detect molecular recurrence or progression in patients with a prior cancer diagnosis; used to identify recurrence before clinical/radiographical evidence and to guide management
    Coverage criteriaPer CMS MolDX: patient history, change-in-management requirement, and demonstrated detection before clinical/radiographic evidence with adequate sensitivity/specificity
    ExamplesSignatera (0340U), Guardant Reveal/Response (0422U), NavDx (0356U) with test- and cancer-specific indications
    Definition — TMB-H per FDA (>=10 mut/Mb)
    DefinitionTMB-H per FDA: tumor mutational burden-high defined as ≥10 mutations per megabase (mut/Mb) for consideration of pembrolizumab in unresectable/metastatic solid tumors
    LimitationsEffectiveness in pediatric and CNS tumors not established per FDA label
    Definition — TMB (short)
    DefinitionTMB: tumor mutational burden — measurement of mutations per megabase in tumor cells used as biomarker for immunotherapy response
    InterpretationMust be interpreted in clinical context and per test-specific reporting
    Definition — MRD testing for solid tumors and hematologic malignancies
    DefinitionMRD testing for solid tumors and hematologic malignancies: molecular assays to detect residual tumor-derived material for surveillance and treatment decisions; policy retired prior MRD criteria and established LCD-based criteria sets
    Coverage dependencyCoverage depends on test clinical validity for the intended use and meeting CMS MolDX LCD conditions
    Definition — MRD testing (operational)
    DefinitionMRD testing (operational): default frequency guidance — once per cancer diagnosis for patients with cancer; once every 12 months for patients without cancer absent guidelines
    When guidelines existFollow national/society guideline-specified regimens when present
    Definition — HLA typing
    DefinitionHLA typing: testing to determine donor and recipient HLA for transplantation to guide donor selection and transplant compatibility
    CoverageCovered for donor or recipient evaluation for bone marrow or solid organ transplantation; investigational for other indications
    Reporting requirementsFor transplant candidates, reporting of class I and II loci per OPTN/requirements is expected